Skip to main content
Torrent Pharmaceuticals Ltd. logo

Torrent Pharmaceuticals Ltd. — Investor Relations & Filings

Ticker · TORNTPHARM ISIN · INE685A01028 LEI · 335800NA6HK275RIJE13 BSE.NS Manufacturing
Open in API
Filings indexed 1,760 across all filing types
Latest filing 2024-09-26 Capital/Financing Update
Country IN India
Listing BSE.NS TORNTPHARM

About Torrent Pharmaceuticals Ltd.

https://www.torrentpharma.com

Torrent Pharmaceuticals Ltd. is a research-driven organization focused on the development, manufacturing, and marketing of generic formulations. The company holds a significant position in therapeutic areas such as cardiovascular, central nervous system, gastrointestinal, diabetology, and anti-infective treatments. It has strategically expanded its portfolio into dermatology, nephrology, and pain management through targeted acquisitions. The firm operates across multiple international markets, supported by advanced research and development centers and manufacturing facilities that adhere to global regulatory standards. Its core operations prioritize chronic therapy leadership and the provision of high-quality healthcare solutions through a robust pipeline of generic and value-added medicines.

Recent filings

Filing Released Lang Actions
Intimation for Incorporation of Wholly Owned Subsidiary (WOS)
Capital/Financing Update Classification · 95% confidence The document is an official letter addressed to the stock exchange (BSE Limited) regarding the incorporation of a wholly owned subsidiary (WOS) by Torrent Pharmaceuticals. It references compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events. The content details the incorporation of the subsidiary, its share capital, ownership, and business purpose. This is a corporate announcement about a capital structure change (incorporation of a subsidiary with share capital details). It is not a full financial report, earnings release, or management discussion. It fits best under Capital/Financing Update (CAP) as it relates to company fundraising and capital structure changes through the creation of a subsidiary. The document length and detail confirm it is not a brief announcement or a report publication notice, but a substantive disclosure under SEBI regulations about capital structure change.
2024-09-26 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release from Torrent Pharmaceuticals Limited dated September 26, 2024, refuting claims about a product failing a quality test by CDSCO. It is a communication clarifying a regulatory or quality issue, not a financial report or detailed regulatory filing. The document is short (4181 characters) and primarily serves as an announcement or statement to the stock exchanges (BSE and NSE) and the public. It does not contain financial data, management discussion, voting results, or detailed governance information. It is not an annual or interim report, audit report, earnings release, or any form of detailed regulatory filing. It is also not a report publication announcement since it does not mention any report being published or attached. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement or clarification to the market about a quality control issue and media claims.
2024-09-26 English
Press Release Attached.
Regulatory Filings Classification · 95% confidence The document is a press release dated September 26, 2024, from Torrent Pharmaceuticals Limited, refuting claims about a product failing a quality test by CDSCO. It is a communication clarifying a regulatory or quality issue, not a financial report or detailed regulatory filing. The document is short (4181 characters) and primarily serves as an announcement or statement to the stock exchanges and public. It does not contain financial data, management changes, voting results, or detailed report content. It is not an earnings release, annual report, or audit report. It is also not a legal proceeding update or a capital/financing update. The document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement addressing a public concern and clarifying company position without fitting into more specific categories.
2024-09-26 English
Intimation of issue of duplicate share certificates
Share Issue/Capital Change Classification · 95% confidence The document is a formal letter addressed to the stock exchanges (BSE and NSE) regarding the issuance of duplicate share certificates. It references Regulation 39 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to share certificate management. The content is about share certificate issuance and confirmation letters to shareholders, not about financial results, management changes, or other report types. The document length is short (1765 characters) and it is an announcement of a corporate action related to shares, specifically duplicate share certificates. This fits best under the category of Share Issue/Capital Change (SHA), which covers announcements regarding share-related changes such as new share issues or certificate issuance. It is not a full report or financial statement, nor a regulatory filing or voting result. Therefore, the classification is SHA with high confidence.
2024-09-25 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to the stock exchanges (BSE and NSE) regarding the issuance of duplicate share certificates. It references Regulation 39 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to share certificate management. The content is about notifying the exchanges of a corporate action related to share certificates, specifically the issuance of duplicates, and includes details of shareholders and certificate numbers. This is not a financial report, earnings release, or management discussion. It is a regulatory announcement about share certificate issuance, which fits best under Regulatory Filings (RNS) as it does not fall under more specific categories like Share Issue/Capital Change or Director's Dealing. The document length is short and it is an announcement rather than a report or detailed filing.
2024-09-25 English
Intimation of Schedule of Investors Meets under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the stock exchanges (BSE and NSE) informing them about the schedule of upcoming investor meetings (Non-Deal Roadshows). It references compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events or information. The content is an announcement of planned investor engagement activities rather than a financial report, earnings release, or detailed presentation. The document length is short (1643 characters) and does not contain financial data or detailed analysis. Therefore, it is best classified as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2024-09-24 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.